Loading...
•
Dec 31, 2025
Coherus Q4 2025 Earnings Report
Revenue increased year over year while the company continued to report significant operating losses as it invested in its oncology pipeline.
Key Takeaways
Coherus reported higher Q4 revenue driven by LOQTORZI growth, but operating losses remained large as R&D spending increased. The company continues transitioning toward an oncology-focused pipeline while reducing debt and maintaining a sizable cash position.
Q4 revenue rose year over year driven primarily by LOQTORZI sales growth.
Operating loss remained significant due to continued R&D investment.
LOQTORZI revenue grew strongly as adoption expanded in nasopharyngeal carcinoma.
The company ended the year with over $172 million in cash, cash equivalents and marketable securities.
Revenue by Segment
Forward Guidance
Management emphasized continued commercialization of LOQTORZI, advancement of oncology pipeline programs, and upcoming clinical data readouts expected in 2026.
Positive Outlook
- LOQTORZI adoption continues to expand with strong revenue growth.
- Multiple clinical programs advancing with expected readouts in 2026.
- Substantial reduction in company debt over the past two years.
- Strong cash position to support development programs.
- Potential partnership and combination therapy opportunities across the pipeline.
Challenges Ahead
- The company continues to generate significant operating losses.
- High R&D spending required to advance multiple oncology programs.
- Revenue remains concentrated in a single commercial product.
- Future funding needs may depend on capital markets or partnerships.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...